Hengrui Medicine gets drug approval for blood disorder treatment

Jiangsu Hengrui Medicine announced that its Hatripopa Ethanolamine Tablets received marketing authorization application acceptance from the National Medical Products Administration. The drug targets adults and children aged 6 years and older with persistent and chronic primary immune thrombocytopenia who have responded inadequately to previous treatments.

The Phase III clinical trial completed in March 2025 met its primary endpoint, showing significant superiority over the control group. The company invested approximately 44.6 billion yuan in developing the tablets.